Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19

BACKGROUND: Controversy remains about the efficacy of tocilizumab (TCZ) for the treatment of severe COVID-19. We aimed to analyze the profile of TCZ-respondent patients. METHODS: We retrospectively analyzed a cohort of patients with severe COVID-19 who received off-label TCZ after recommendation by...

Descripción completa

Detalles Bibliográficos
Autores principales: San-Juan, Rafael, Fernández-Ruiz, Mario, López-Medrano, Francisco, Carretero, Octavio, Lalueza, Antonio, Maestro de la Calle, Guillermo, Pérez-Jacoiste Asín, María Asunción, Bueno, Héctor, Caro-Teller, José Manuel, Catalán, Mercedes, de la Calle, Cristina, García-García, Rocío, Gómez, Carlos, Laguna-Goya, Rocío, Lizasoáin, Manuel, Martínez-López, Joaquín, Origüen, Julia, Sevillano, Ángel, Gutiérrez, Eduardo, de Miguel, Borja, Aguilar, Fernando, Parra, Patricia, Ripoll, Mar, Ruiz-Merlo, Tamara, Trujillo, Hernando, Pablos, José Luis, Paz-Artal, Estela, Lumbreras, Carlos, Aguado, José María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783837/
https://www.ncbi.nlm.nih.gov/pubmed/35081417
http://dx.doi.org/10.1016/j.ijid.2022.01.040

Ejemplares similares

Ejemplares similares